Low Dose Naltrexone in the Treatment of Fibromyalgia

被引：21

作者：

Metyas, Samy ^{[1
]}

Chen, Christina L. ^{[1
]}

Yeter, Karen ^{[1
]}

Solyman, John

Arkfeld, Daniel G. ^{[1
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Rheumatol, Covina, CA USA

来源：

CURRENT RHEUMATOLOGY REVIEWS | 2018年 / 14卷 / 02期

关键词：

Fibromyalgia; low dose naltrexone; fatigue; CAMs; treatment; endorphin function;

D O I：

10.2174/1573397113666170321120329

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: ConclusionFibromyalgia is a chronic pain disorder characterized by diffuse musculoskeletal pain, fatigue, sleep disturbance and cognitive impairment. Objective: A significant number of fibromyalgia patients do not respond adequately to the current drugs approved by the Food and Drug Administration (FDA) for fibromyalgia treatment including pregabalin, milnacipran, duloxetine. Thus, there is still a need for adjunctive therapies. Method: Naltrexone is an opioid receptor antagonist used to treat alcohol and opioid dependence. It is hypothesized that low dose naltrexone causes transient blockade of opioid receptors centrally resulting in a rebound of endorphin function which may attenuate pain in fibromyalgia. Results: Two small prospective pilot studies have previously shown that treatment with low dose naltrexone may be an effective, safe, and inexpensive treatment for fibromyalgia. Conclusion: This prospective study lends further support to the preliminary body of evidence that naltrexone is a well tolerated and likely effective treatment option in the community setting. Further large prospective controlled trials are still needed.

引用

页码：177 / 180

页数：4

共 29 条

[21] Glia as the "bad guys": Implications for improving clinical pain control and the clinical utility of opioids [J].

Watkins, Linda R. ;

Hutchinson, Mark R. ;

Ledeboer, Annemarie ;

Wieseler-Frank, Julie ;

Milligan, Erin D. ;

Maier, Steven F. .

BRAIN BEHAVIOR AND IMMUNITY, 2007, 21 (02) :131-146

[22] FIBROMYALGIA SYNDROME - NEW ASSOCIATIONS [J].

WAYLONIS, GW ;

HECK, W .

AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 1992, 71 (06) :343-348

[23] Immune-to-brain communication dynamically modulates pain: Physiological and pathological consequences [J].

Wieseler-Frank, J ;

Maier, SF ;

Watkins, LR .

BRAIN BEHAVIOR AND IMMUNITY, 2005, 19 (02) :104-111

[24] THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY 1990 CRITERIA FOR THE CLASSIFICATION OF FIBROMYALGIA - REPORT OF THE MULTICENTER CRITERIA COMMITTEE [J].

WOLFE, F ;

SMYTHE, HA ;

YUNUS, MB ;

BENNETT, RM ;

BOMBARDIER, C ;

GOLDENBERG, DL ;

TUGWELL, P ;

CAMPBELL, SM ;

ABELES, M ;

CLARK, P ;

FAM, AG ;

FARBER, SJ ;

FIECHTNER, JJ ;

FRANKLIN, CM ;

GATTER, RA ;

HAMATY, D ;

LESSARD, J ;

LICHTBROUN, AS ;

MASI, AT ;

MCCAIN, GA ;

REYNOLDS, WJ ;

ROMANO, TJ ;

RUSSELL, IJ ;

SHEON, RP .

ARTHRITIS AND RHEUMATISM, 1990, 33 (02) :160-172

[25] The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity [J].

Wolfe, Frederick ;

Clauw, Daniel J. ;

Fitzcharles, Mary-Ann ;

Goldenberg, Don L. ;

Katz, Robert S. ;

Mease, Philip ;

Russell, Anthony S. ;

Russell, I. Jon ;

Winfield, John B. ;

Yunus, Muhammad B. .

ARTHRITIS CARE & RESEARCH, 2010, 62 (05) :600-610

[26] The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain [J].

Younger, Jarred ;

Parkitny, Luke ;

McLain, David .

CLINICAL RHEUMATOLOGY, 2014, 33 (04) :451-459

[27] Low-Dose Naltrexone for the Treatment of Fibromyalgia [J].

Younger, Jarred ;

Noor, Noorulain ;

Mccue, Rebecca ;

Mackey, Sean .

ARTHRITIS AND RHEUMATISM, 2013, 65 (02) :529-538

[28] Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study [J].

Younger, Jarred ;

Mackey, Sean .

PAIN MEDICINE, 2009, 10 (04) :663-672

[29]

YUNUS MB, 1992, J RHEUMATOL, V19, P846

← 1 2 3 →